- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-7799
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Tips for erythropoiesis-stimulating agent treatment of renal anemia ; volume:24 ; number:1 ; day:16 ; month:10 ; year:2019 ; pages:105-106 ; date:1.2020
Clinical and experimental nephrology ; 24, Heft 1 (16.10.2019), 105-106, 1.2020
- Urheber
-
Tomosugi, Naohisa
Koshino, Yoshitaka
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10157-019-01791-w
- URN
-
urn:nbn:de:101:1-2020041402581015182797
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tomosugi, Naohisa
- Koshino, Yoshitaka
- SpringerLink (Online service)
Ähnliche Objekte (12)
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy
Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis
Erythroid-intrinsic activation of TLR8 impairs erythropoiesis in inherited anemia
Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy
Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis
Erythroid-intrinsic activation of TLR8 impairs erythropoiesis in inherited anemia
Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy
Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis
Erythroid-intrinsic activation of TLR8 impairs erythropoiesis in inherited anemia
Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient